Immunotherapy for angiogenic disease

Patent metadata

Field	Value
Publication number	US-10525096-B2
Application number	US-201515534895-A
Country	US
Kind code	B2
Filing date	Dec 10, 2015
Priority date	Dec 11, 2014
Publication date	Jan 7, 2020
Grant date	Jan 7, 2020

Abstract

The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.

First claim

The invention claimed is:

1. A method for treating an intraocular angiogenic disease, comprising:
administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a WT1 peptide, wherein the WT1 peptide has 7 to 30 amino acids,
wherein the WT1 peptide comprises a sequence selected from the group consisting of (a), (b), (c) and (d):
(a)

(SEQ ID NO: 1)

Arg Met Phe Pro Asn Ala Pro Tyr Leu,

(b)

(SEQ ID NO: 19)

Cys Tyr Thr Trp Asn Gln Met Asn Leu,

(c)

(SEQ ID NO: 27)

Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser

Ala Tyr Gly Ser Leu Gly,

 and
(d)

(SEQ ID NO: 32)

Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His

Ser Arg Lys His;

 and
wherein the intraocular angiogenic disease is at least one selected from the group consisting of wet-type age-related macular degeneration, myopic macular degeneration, angioid streaks, central serous chorioretinopathy, various types of retinal pigment epitheliopathy, choroidal atrophy, choroideremia, choroidal osteoma, diabetic retinopathy, retinopathy of prematurity, rubeotic glaucoma, and corneal neovascularization.

2. The method of claim 1 , wherein the WT1 peptide has a binding ability to an HLA molecule.

3. The method of claim 1 , wherein the WT1 peptide is capable of activating a killer T cell or a helper T cell.

4. The method of claim 1 , wherein the pharmaceutical composition is administered by intracutaneous administration, subcutaneous administration, percutaneous administration, or transmucosal administration.

5. The method of claim 1 , wherein the pharmaceutical composition is administered in combination with a drug for treatment of an angiogenic disease.

6. The method of claim 1 , wherein the WT1 peptide consists of a sequence selected from the group consisting of (a), (b), (c) and (d):
(a) Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 1),
(b) Cys Tyr Thr Trp Asn Gin Met Asn Leu (SEQ ID NO: 19),
(c) Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser Ala Tyr Gly Ser Leu Gly (SEQ ID NO: 27), and
(d) Lys Arg Tyr Phe Lys Leu Ser His Leu Gin Met His Ser Arg Lys His (SEQ ID NO: 32).

Assignees

• Int Inst Cancer Immunology Inc

Inventors

• Sugiyama Haruo

Classifications

• A61K9/006

  Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays · CPC title

• C07K7/06

  having 5 to 11 amino acids · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• C07K14/4748

  Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title

• A61K38/02 Primary

  Peptides of undefined number of amino acids; Derivatives thereof · CPC title